First Republic Investment Management Inc. boosted its position in shares of Icon Plc (NASDAQ:ICLR) by 22.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,988 shares of the medical research company’s stock after acquiring an additional 1,458 shares during the period. First Republic Investment Management Inc.’s holdings in Icon were worth $910,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ICLR. IHT Wealth Management LLC grew its stake in Icon by 16.9% in the 2nd quarter. IHT Wealth Management LLC now owns 166 shares of the medical research company’s stock worth $223,000 after buying an additional 24 shares in the last quarter. Acrospire Investment Management LLC lifted its holdings in shares of Icon by 20.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,195 shares of the medical research company’s stock worth $117,000 after acquiring an additional 200 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Icon by 20.7% in the 2nd quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock worth $133,000 after acquiring an additional 217 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Icon in the 3rd quarter worth approximately $148,000. Finally, Commonwealth Equity Services Inc bought a new stake in shares of Icon in the 3rd quarter worth approximately $208,000. 89.95% of the stock is owned by institutional investors.

Shares of Icon Plc (ICLR) opened at $113.52 on Friday. Icon Plc has a 1-year low of $73.76 and a 1-year high of $124.48. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. The company has a market cap of $6,166.29, a price-to-earnings ratio of 21.86, a P/E/G ratio of 1.76 and a beta of 0.56.

Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company had revenue of $440.30 million during the quarter, compared to analyst estimates of $438.09 million. During the same period in the prior year, the business posted $1.19 EPS. The firm’s revenue was up 4.8% compared to the same quarter last year. equities analysts anticipate that Icon Plc will post 5.37 earnings per share for the current fiscal year.

ICLR has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Icon from a “hold” rating to a “buy” rating and set a $120.00 price objective for the company in a report on Thursday, August 24th. ValuEngine upgraded shares of Icon from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Jefferies Group restated a “buy” rating and issued a $122.00 price objective on shares of Icon in a report on Tuesday, September 12th. Bank of America initiated coverage on shares of Icon in a report on Monday, September 11th. They issued a “buy” rating and a $128.00 price objective for the company. Finally, Robert W. Baird restated a “buy” rating and issued a $123.00 price objective on shares of Icon in a report on Thursday, October 12th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Icon presently has a consensus rating of “Buy” and an average price target of $121.00.

COPYRIGHT VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/15/icon-plc-iclr-position-boosted-by-first-republic-investment-management-inc.html.

Icon Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Stock Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related stocks with our FREE daily email newsletter.